An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.
Lebanon Cardiology Associates teamed with The Good Samaritan Hospital to implement one of the top 15% performing emergency cardiac catheterization teams treating heart attacks in the United States.
The portable magnetometer is being developed at the University of Leeds, with funding from the Engineering and Physical Sciences Research Council (EPSRC) playing a key role.
Even healthy people exposed to ultrafine particulate pollution associated with traffic and fossil-fuel combustion for just two hours show changes in heart rhythm and evidence of clot formation that may herald the potential for serious cardiac events, according to research from the Environmental Protection Agency.
UCLA researchers have discovered that a specific type of medication used to treat cardiovascular conditions such as hypertension, angina and abnormal heart rhythms may also decrease the risk of developing Parkinson's disease.
Ushering in a new era in comprehensive cardiac care, the Vivian and Seymour Milstein Family Heart Center celebrated its opening today at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has received FDA approval of its PMA (Pre-Market Approval) supplement, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) for Destination Therapy (DT).
National medical and lifestyle experts have been brought together by sanofi-aventis U.S. to help aging Americans learn to live life more fully despite a serious and increasingly prevalent heart condition – atrial fibrillation (AFib), a type of irregular heartbeat.
The sporting world lost two young athletes this month to sudden cardiac death. Preliminary autopsy reports indicate that Chicago Bears defensive end Gaines Adams, 26, and Southern Indiana center Jeron Lewis, 21, both had enlarged hearts at the time of their death.
Scientists at the University of Leicester are 'painting' the colours of the heart in an innovative project that has potential to bring benefits for millions of people with irregular heart rhythm.
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the first implantations of BIOTRONIK’s new leadless cardiac monitoring device performed by a team of physicians led by Professor Dr. Gerhard Hindricks, Director, Electrophysiology Department at the Leipzig Heart Center in Leipzig, Germany.
ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).
Cardima, Inc., a medical device company focused on the diagnosis and treatment of atrial fibrillation (AF), has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to re-enter the Japanese market with its family of guidewire-based, multi-electrode PATHFINDER® diagnostic mapping catheters.
University at Buffalo biophysicists have found a protein in tarantula venom that shows promise as a potential therapy for muscular dystrophy (MD). They have formed a start-up biotech company in Buffalo -- Rose Pharmaceuticals -- to advance the drug to clinical trials.
A large multicenter international trial found that the image quality of multi-detector computed tomography (MDCT) scans, used for the noninvasive detection of coronary artery disease, can be significantly affected by patient characteristics such as ethnicity, body mass index (BMI), and heart rate, according to a study in the January issue of the American Journal of Roentgenology.
A study of heart failure patients who meet national guidelines for devices that stabilize and strengthen the heart's electrical system found that only half of eligible patients received the devices.
Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.
Hansen Medical, Inc. announced today that it has entered into a Confidential Settlement Agreement (the "Settlement Agreement") with Luna Innovations Incorporated (NASDAQ: LUNA) and its wholly-owned subsidiary, Luna Technologies, Inc.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.